Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PAZ-417 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PAZ-417 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PAZ-417 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria 1. Men aged 20 to 45 years inclusive (healthy young male subjects) and ≥65 years inclusive (healthy elderly male subjects) 2. Nonsmoker or smoker of fewer than 10 cigarettes per day. 3. Healthy as determined by the investigator on the basis of medical history, physical examinatio...
Top 20 of 24 competitors
PAZ-417 is an investigational small molecule being studied for Alzheimer Disease. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being developed by Pfizer, Inc. as a potential treatment for this neurological condition.
PAZ-417's molecular target has not been disclosed. The drug is a small molecule being investigated for Alzheimer Disease, but its specific mechanism of action is not publicly available from the clinical trial information provided.
PAZ-417 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this investigational drug for Alzheimer Disease.
PAZ-417 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is still in early-stage clinical trials to evaluate its safety, tolerability, and activity in humans.
PAZ-417 has one completed Phase 1 clinical trial registered as NCT00684710. This study evaluated the safety, tolerability, and activity of a single dose of PAZ-417 in healthy Japanese male subjects aged 20 years and older. The trial enrolled 56 participants and was placebo-controlled and double-blinded.
No alternative names for PAZ-417 have been identified. The drug is known only by its development code PAZ-417 and is being studied by Pfizer, Inc. for Alzheimer Disease. No other names or aliases for this compound have been reported.